The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy
Open accessAbstract
Summary: Objective: To compare the effectiveness of controlled‐released carbamazepine (CR‐CBZ) to levetiracetam (LEV) and to lamotrigine (LTG) in elderly patients with newly diagnosed focal epilepsy. Methods: Randomized, double‐blind, parallel‐group trial conducted between January 2007 and August 2011, in 47 ambulatory or hospital sites in Germany, Austria, or Switzerland. Eligible participants were aged ≥60, had new‐onset epilepsy, had no acute illness as the cause of their seizures, and had no contraindication to the drugs in the trial. Patients were randomized 1:1:1 to CR‐CBZ, LTG, or LEV. Doses were up‐titrated for 6 weeks and could be maintained or adjusted depending on seizure relapse or tolerability over an additional period of 52 weeks. Primary outcome was the retention to treatment at week 58; secondary measures related to seizure and adverse event frequency. Results: Of 361 randomized patients, 359 were included (CR‐CBZ n = 121, LTG n = 117, LEV n = 122) in the modified intent‐to‐treat population (mean age [range] 71.4 [60–95] years). At week 58, the retention rate for LEV was significantly higher than for CR‐CBZ (61.5% vs. 45.8%, p = 0.02), and similar to LTG (55.6%). Seizure freedom rates at weeks 30 and 58 were not different across the groups. Twice as many patients receiving CR‐CBZ discontinued due to adverse events or death compared to those in the LEV group (32.2% vs. 17.2%; odds ratio 2.28, 95% confidence interval [CI] 1.25–4.19, p = 0.007), whereas discontinuation was intermediate for LTG (26.3%). Median daily doses of completers (n = 195) were CR‐CBZ 380.0 mg/day (333.0–384.0), LTG 95 mg/day (94.0–97.0), and LEV 950 mg/day (940.0–985.0). Significance: In the initial monotherapy of focal epilepsy in the elderly, 1‐year retention to LEV was higher compared to CR‐CBZ due to better tolerability. Retention of LTG was intermediate and close to LEV, but did not differ significantly from either comparators. NCT00438451, www.clinicaltrials.gov.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108
Cited by
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
30 years of second-generation antiseizure medications: impact and future perspectives
Perucca, E., Brodie, M. J., Kwan, P., & Tomson, T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30035-1 · Cited by 261
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
Metadata
- Authors
- Werhahn, K. J., Trinka, E., Dobesberger, J., Unterberger, I., Baum, P., Deckert‐Schmitz, M., Kniess, T., Schmitz, B., Bernedo, V., Ruckes, C., Ehrlich, A., & Krämer, G.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2015-02-12
- Volume
- 56
- Issue
- 3
- Pages
- 450-459
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2066622149
- Cited by
- 177
- References
- 1
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. https://app.cochat.ai/papers/10.1111/epi.12926
- The paper
- Werhahn, K. J., Trinka, E., Dobesberger, J., Unterberger, I., Baum, P., Deckert‐Schmitz, M., Kniess, T., Schmitz, B., Bernedo, V., Ruckes, C., Ehrlich, A., & Krämer, G. (2015). A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia. https://doi.org/10.1111/epi.12926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.